Go Pro
NASDAQ:BRTX

Biorestorative Therapies Q2 2026 Earnings Report

Biorestorative Therapies logo
$0.22 +0.01 (+4.51%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.60 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Biorestorative Therapies Earnings Headlines

Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update
Buy THIS potential Musk supplier before Wednesday
A little-known company trading under $1 could become Elon Musk's next supplier, with a possible announcement expected by Wednesday, August 26. Tech investing veteran Jeff Brown notes that the last time Musk struck a deal with a small company in this sector, the stock soared nearly five times in a single session. He has reopened his strategy session with full details on this potential opportunity.tc pixel
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy. Biorestorative Therapies’ candidate has completed early-stage clinical evaluation and is advancing through planned trials to assess safety and efficacy in reducing the duration and severity of oral mucositis. Preclinical studies have also been conducted to explore additional indications, including inflammatory and degenerative conditions.

Headquartered in Malvern, Pennsylvania, Biorestorative Therapies manages its research, manufacturing and clinical development activities in the United States. The company works with clinical research organizations and academic centers to support its ongoing trials and maintains a leadership team with experience spanning cell therapy, clinical development and regulatory affairs. Biorestorative Therapies continues to pursue partnerships to expand its pipeline and accelerate the path to potential regulatory approval.

View Biorestorative Therapies Profile